Key facts
- Our Dutch head office is located in Utrecht.
- BMS has been active in the Netherlands for more than 50 years.
- BMS's first European CAR-T facility is in the Leiden Bio Science Park.
- Every day, our people work together to save the lives of patients with solid and blood cancers, heart disease and autoimmune diseases.
- Through more than 50 active clinical trials, we ensure that Dutch patients have access to the most promising new medicines.
BMS worldwide
Update 2026
Chief Executive Officer:
Headquarters:
Princeton, New Jersey, USA
Business:
Biopharmaceuticals
Website:
NYSE Listing:
BMY
Net Global Sales:
$48.2 billion in 2025
R&D Investment:
$10.0 billion in 2025
Principal Locations:
BMS in the Netherlands
Update 2026
General Manager:
Karen Costello
Local Headquarters:
Orteliuslaan 1000
3528 BD Utrecht
Key Therapeutic Areas:
Oncology
Hematology
Cardiovascular
Immunology